On the upside
Jefferies & Co. initiated coverage of Jazz Pharmaceuticals (Nasdaq: JAZZ) with a Buy rating.
Macquarie Research analyst Jonathan Grobert said that Affymetrix (Nasdaq: AFFX) is a compelling acquisition target.
Valassis Communications (NYSE: VCI) forecast 2010 results above expectations.